Description of the Ability to Learn How to Handle Inhaler Devices in COPD
Status:
Unknown status
Trial end date:
2017-08-01
Target enrollment:
Participant gender:
Summary
Chronic Obstructive Pulmonary Disease (COPD) is the fourth leading cause of death in the
world and further increase in its prevalence and mortality has been predicted. Currently, the
main long-term treatments are the long-acting beta-2 agonist, indacaterol, salmeterol and the
anticholinergic drug, tiotropium and glycopyrronium, used alone or in combination:
- long-acting beta-2 agonist with corticosteroid (e.g. salmeterol/fluticasone),
- long-acting beta-2 agonist with anticholinergic (e.g. indacatetrol/glycopyrronium).
These drugs are delivered to the lung using different inhaler devices such as Breezhaler ®,
Handihaler® and Diskus®.
Phase:
Phase 4
Details
Lead Sponsor:
University Hospital, Bordeaux
Treatments:
Fluticasone Propionate, Salmeterol Xinafoate Drug Combination Fluticasone-Salmeterol Drug Combination Tiotropium Bromide